Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

M. G. Kris; R. J. Gralla; D. P. Kelsen; E. S. Casper; M. T. Burke; J. J. Fiore; I. R. Cibas; R. T. Heelan

doi:10.1097/00000421-198510000-00007

Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

M. G. Kris, R. J. Gralla, D. P. Kelsen, E. S. Casper, M. T. Burke, J. J. Fiore, I. R. Cibas, R. T. Heelan

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m² orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

Original language	English (US)
Pages (from-to)	377-379
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	8
Issue number	5
DOIs	https://doi.org/10.1097/00000421-198510000-00007
State	Published - 1985
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-198510000-00007

Cite this

@article{f58f35d92bbc4eeca22170ea226fdb64,

title = "Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer",

abstract = "4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.",

author = "Kris, {M. G.} and Gralla, {R. J.} and Kelsen, {D. P.} and Casper, {E. S.} and Burke, {M. T.} and Fiore, {J. J.} and Cibas, {I. R.} and Heelan, {R. T.}",

year = "1985",

doi = "10.1097/00000421-198510000-00007",

language = "English (US)",

volume = "8",

pages = "377--379",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

AU - Kris, M. G.

AU - Gralla, R. J.

AU - Kelsen, D. P.

AU - Casper, E. S.

AU - Burke, M. T.

AU - Fiore, J. J.

AU - Cibas, I. R.

AU - Heelan, R. T.

PY - 1985

Y1 - 1985

N2 - 4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

AB - 4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

UR - http://www.scopus.com/inward/record.url?scp=0022358221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022358221&partnerID=8YFLogxK

U2 - 10.1097/00000421-198510000-00007

DO - 10.1097/00000421-198510000-00007

M3 - Article

C2 - 3864366

AN - SCOPUS:0022358221

SN - 0277-3732

VL - 8

SP - 377

EP - 379

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 5

ER -

Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this